NCT04448886: A trial that was reported late by Ana C Garrido-Castro, MD
This trial has reported, although it was 31 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04448886 |
|---|---|
| Title | Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 23, 2020 |
| Completion date | March 9, 2024 |
| Required reporting date | March 9, 2025, midnight |
| Actual reporting date | April 9, 2025 |
| Date last checked at ClinicalTrials.gov | Aug. 1, 2025 |
| Days late | 31 |